This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wysocki, M. Articles by Braide, M. Search for Related Content PubMed PubMed Citation Articles by Wysocki, M. Articles by Braide, M. Social Bookmarking                         What's this?

Hemorheologic Effects of Vasodilation in Essential Hypertension

Institute of Internal Medicine, Department of Medicine, Sahlgrenska University Hospital

Ove K. Andersson

Institute of Internal Medicine, Department of Medicine, Sahlgrenska University Hospital

Bengt Persson

Institute of Internal Medicine, Department of Medicine, Sahlgrenska University Hospital

Ulf Bagge

Institute of Anatomy and Cell Biology, Department of Anatomy, University of Göteborg, Sweden

Magnus Braide

Institute of Anatomy and Cell Biology, Department of Anatomy, University of Göteborg, Sweden

Arterial hypertension is often associated with plasma volume contraction and hemocon centration, which negatively affect the vascular flow resistance and microcirculation. Since some antihypertensive drugs can affect blood rheology, the purpose of this study was to evaluate whether acute and long-term arterial vasodilation with cadralazine influ ences rheologic parameters in essential hypertension. Twelve patients with unsatisfacto rily controlled essential hypertension were studied. In the acute double-blind phase of the study the patients were allocated to treatment with either cadralazine or placebo. Intraarterial blood pressure, cardiac output (dye dilution), and blood rheology (viscosity, hematocrit) were registered before and after the first dose of cadralazine. Then 9 patients (3 dropouts) were treated with cadralazine and placebo during two four-week crossover periods and continued with cadralazine medication during the eight-week open phase of the study. Blood pressure and blood hemoglobin were followed during long-term treatment.

A single oral dose of cadralazine caused vasodilation (total peripheral resistance index decreased from 45 to 33 U x m2, P < 0.05), which was accompanied by hemodi lution (hematocrit declined from 46.9% to 42.5%, P < 0.05) and a blood viscosity reduction of more than 10%. Viscosity of 45% suspension of erythrocytes in plasma was also reduced, suggesting a possible modification of the microrheologic factors. The changes in total peripheral resistance correlated negatively with the changes in hemat ocrit. An antihypertensive effect of cadralazine was still observed during the chronic phase of the study, which was not accompanied by hemodilution. It is concluded that arterial vasodilation with cadralazine reduces flow resistance in the circulatory system in hypertension and has acute rheologic effects that disappear during chronic medication.

Angiology, Vol. 47, No. 9, 869-878 (1996)
DOI: 10.1177/000331979604700905


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?